Literature DB >> 11078976

Clinical use of recombinant human TSH in thyroid cancer patients.

M Schlumberger1, M Ricard, F Pacini.   

Abstract

Recombinant human TSH (rhTSH) is an effective and safe alternative to thyroid hormone withdrawal during the post-surgical follow-up of papillary and follicular thyroid cancer. Its clinical efficiency for the detection of persistent and recurrent disease is similar to that of thyroid hormone withdrawal. The main purpose for its use is to avoid hypothyroidism.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 11078976     DOI： 10.1530/eje.0.1430557

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN： 0804-4643            Impact factor:   6.664


  4 in total

1.  Radioiodine ablation and therapy in differentiated thyroid cancer under stimulation with recombinant human thyroid-stimulating hormone.

Authors:  G Berg; G Lindstedt; M Suurküla; S Jansson
Journal:  J Endocrinol Invest       Date:  2002-01       Impact factor: 4.256

2.  Recombinant human TSH-aided radioiodine treatment of advanced differentiated thyroid carcinoma: a single-centre study of 54 patients.

Authors:  Barbara Jarzab; Daria Handkiewicz-Junak; Józef Roskosz; Zbigniew Puch; Zbigniew Wygoda; Aleksandra Kukulska; Beata Jurecka-Lubieniecka; Kornelia Hasse-Lazar; Maria Turska; Aleksander Zajusz
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-05-29       Impact factor: 9.236

3.  A sensitive Tg assay or rhTSH stimulated Tg: what's the best in the long-term follow-up of patients with differentiated thyroid carcinoma?

Authors:  Adrienne C M Persoon; Pieter L Jager; Wim J Sluiter; John T M Plukker; Bruce H R Wolffenbuttel; Thera P Links
Journal:  PLoS One       Date:  2007-08-29       Impact factor: 3.240

4.  Strong Neck Accumulation of 131I Is a Predictor of Incomplete Low-Dose Radioiodine Remnant Ablation Using Recombinant Human Thyroid-Stimulating Hormone.

Authors:  Keisuke Enomoto; Yoshiharu Sakata; Kazuyuki Izumi; Yukinori Takenaka; Miki Nagai; Kazuya Takeda; Yukie Enomoto; Atsuhiko Uno
Journal:  Medicine (Baltimore)       Date:  2015-09       Impact factor: 1.817
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.